Two independent teams of researchers have identified a role for enhanced activation of the signaling protein Notch in tumors characterized by inactivation of either the TSC1 or the TSC2 protein. These data provide a rationale for testing whether Notch inhibitors are of benefit to those with TSC-associated tumors.